Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 1-10 of 12 (Search time: 0.002 seconds).
previous
1
2
next
Item hits:
Preview
Issue Date
Title
Author(s)
2013
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
Branford, S.
;
Yeung, D.
;
Ross, D.
;
Prime, J.
;
Field, C.
;
Altamura, H.
;
Yeoman, A.
;
Georgievski, J.
;
Jamison, B.
;
Phillis, S.
;
Sullivan, B.
;
Briggs, N.
;
Hertzberg, M.
;
Seymour, J.
;
Reynolds, J.
;
Hughes, T.
2013
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
Ross, D.
;
Branford, S.
;
Seymour, J.
;
Schwarer, A.
;
Arthur, C.
;
Yeung, D.
;
Dang, P.
;
Goyne, J.
;
Slader, C.
;
Filshie, R.
;
Mills, A.
;
Vaz de Melo, J.
;
White, D.
;
Grigg, A.
;
Hughes, T.
2013
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy
Angelini, S.
;
Soverini, S.
;
Ravegnini, G.
;
Barnett, M.
;
Turrini, E.
;
Thornquist, M.
;
Pane, F.
;
Hughes, T.
;
White, D.
;
Radich, J.
;
Kim, D.
;
Saglio, G.
;
Cilloni, D.
;
Iacobucci, I.
;
Perini, G.
;
Woodman, R.
;
Cantelli-Forti, G.
;
Baccarani, M.
;
Hrelia, P.
;
Martinelli, G.
2010
Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemia
Saglio, G.
;
Kim, D.
;
Issaragrisil, S.
;
le Coutre, P.
;
Etienne, G.
;
Lobo, C.
;
Pasquini, R.
;
Clark, R.
;
Hochhaus, A.
;
Hughes, T.
;
Gallagher, N.
;
Hoenekopp, A.
;
Haque, A.
;
Dong, M.
;
Larson, R.
;
Kantarjian, H.
2010
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
Hughes, T.
;
Hochhaus, A.
;
Branford, S.
;
Muller, M.
;
Kaeda, J.
;
Foroni, L.
;
Druker, B.
;
Guilhot, F.
;
Larson, R.
;
O'Brien, S.
;
Rudoltz, M.
;
Mone, M.
;
Wehrle, E.
;
Modur, V.
;
Goldman, J.
;
Radich, J.
2010
Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: A mechanism for improved insulin sensitivity in Type 2 diabetic CML patients?
Fitter, S.
;
Vandyke, K.
;
Schultz, C.
;
White, D.
;
Hughes, T.
;
Zannettino, A.
2012
Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib response
White, D.
;
Hughes, T.
2013
Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: Evidence for site-specific skeletal effects
Vandyke, K.
;
Fitter, S.
;
Drew, J.
;
Fukumoto, S.
;
Schultz, C.
;
Sims, N.
;
Yeung, D.
;
Hughes, T.
;
Zannettino, A.
2010
Phase III, randomized, open-label study of daily Imatinib Mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study
Cortes, A.
;
Baccarani, M.
;
Guilhot, F.
;
Druker, B.
;
Branford, S.
;
Kim, D.
;
Pane, F.
;
Pasquini, R.
;
Goldberg, S.
;
Kalaycio, M.
;
Moiraghi, B.
;
Rowe, J.
;
Tothova, E.
;
de Souza, C.
;
Rudoltz, M.
;
Yu, R.
;
Krahnke, T.
;
Kantarjian, H.
;
Radich, J.
;
Hughes, T.
2010
Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with Imatinib
White, D.
;
Dang, P.
;
Engler, J.
;
Frede, A.
;
Osborn, M.
;
Saunders, V.
;
Manley, P.
;
Zrim, S.
;
Hughes, T.
Discover
Author
2
Fitter, S.
2
Guilhot, F.
2
Hochhaus, A.
2
Kantarjian, H.
2
Larson, R.
2
Martinelli, G.
2
Pane, F.
2
Pasquini, R.
2
Ross, D.
2
Rudoltz, M.
.
< previous
next >
Subject
12
Female
12
Humans
11
Imatinib Mesylate
11
Piperazines
10
Antineoplastic Agents
10
Benzamides
10
Middle Aged
9
Adult
9
Aged
8
Leukemia, Myelogenous, Chronic, B...
.
next >
Date issued
1
2017
4
2013
1
2012
1
2011
5
2010